

FOR IMMEDIATE RELEASE

TARGAN Secures \$100m Growth Financing From Symbiotic Capital

Funding supports global scale-up of WingScan™ and TARGAN's next generation of technologies

Raleigh, North Carolina, United States, March 3, 2026 — [TARGAN](#), a leading animal health and AgTech company, today announced a \$100 million financing agreement with Symbiotic Capital, a private credit fund specializing in the healthcare sector. The deal closed in December 2025 and included an initial funded tranche of \$30 million.

The financing provides additional capital to support the company's continued growth as it accelerates commercial deployment of its flagship technology, WingScan™. Proceeds have also strengthened TARGAN's balance sheet by replacing its previous senior lender, Live Oak Bank, and providing liquidity and flexibility to bring new technologies to market in 2026/27.

Ramin Karimpour, CEO and Founder of TARGAN, said: "We are entering a period of extraordinary growth, and this financing enhances our ability to deliver technologies that address some of the most pressing challenges in global food production. WingScan is seeing strong momentum across the United States, Europe, and South America, with new markets coming online every month. I'm looking forward to scaling our operations and investing in the infrastructure that will support the next wave of technologies we bring to market."

"TARGAN has established itself as a true pioneer in the animal health space, bringing automation, precision, and data-driven decision-making to the animal protein production industry at scale," said Chris York, Senior Managing Director at Symbiotic Capital. "We have been impressed by the company's strong commercial traction. The level of adoption being seen with WingScan reflects the strength of the solution and the growing demand for innovation across the animal health industry. We are pleased to support TARGAN in this next phase of expansion."

The transaction follows a period of rapid commercial expansion. Revenue more than doubled from 2024 to 2025, and the company expects to deliver further significant growth in 2025 to 2026, with revenues projected to continue to increase year on year. With increasing deployment of WingScan across the globe, the company is focused on expanding capacity, strengthening regional service infrastructure, and delivering data-driven technologies that improve efficiency, accuracy, and animal welfare at all stages of the poultry production value chain.

ENDS

About Symbiotic Capital

Symbiotic Capital is a healthcare credit platform that brings together decades of experience across healthcare, finance, and entrepreneurship. Its integration into a global-healthcare ecosystem empowers it to provide lending solutions to fuel the growth of established healthcare companies around the world.

About TARGAN

TARGAN is an innovative animal AgTech systems company focused on transforming animal protein production industries worldwide. Founded in 2015 and based in Raleigh, North

Carolina, the company's mission is to provide affordable, individualized technologies that will improve speed, accuracy and animal welfare. For more information, visit <https://www.targan.com>.

TARGAN is a registered trademark of TARGAN in the United States and other countries.

Media Contacts:

Charlotte Baker
+44 (0)20 8647 4467
charlotte.baker@garnettkeeler.com

Carlos Bautista
carlos.bautista@targan.com